CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC) will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
